Changing the Paradigm for Patients With Treatment-Resistant Depression
The U.S. Food and Drug Administration on March 5 approved SPRAVATO™ (esketamine) CIII nasal spray for the treatment of treatment-resistant depression. Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, is a...
Consortium Sheds New Light on Brain Disorders
More than two dozen researchers at the Icahn School of Medicine at Mount Sinai are advancing brain science by mapping the complex molecular underpinnings of autism spectrum disorder, schizophrenia, and bipolar disorder through their work in the National...
Innovations in Psychiatry: New Treatments for Depression
The Department of Psychiatry’s seventh annual symposium took place on Friday, February 8. The speakers covered emerging treatments for depression including ketamine, deep brain stimulation, and personalized treatment. “This symposium was an...
APA 2019: Mount Sinai’s Presentations
This year’s American Psychiatric Association (APA) conference takes place May 18-22 in San Francisco. The schedule of sessions presented by faculty from the Department of Psychiatry is listed below. Veerle Bergink, MD, PhD, will speak on psychiatric illness during and...
NARSAD Awardees
The 2018 NARSAD Young Investigator grantees from the Brain and Behavior Research Foundation include four faculty members from the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai. Their research aims are listed below. ...
CARES: A Unique Program for Teens
For more than three decades, the Comprehensive Adolescent Rehabilitation and Education Service (CARES) at Mount Sinai Morningside has been helping high school students with mental health and/or substance abuse issues turn their lives around. The program integrates...